Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pexidartinib - Plexxikon

Drug Profile

Pexidartinib - Plexxikon

Alternative Names: Pexidartinib hydrochloride; Plexxikon 3397; PLX-3397; TURALIO

Latest Information Update: 01 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Plexxikon
  • Developer Array BioPharma; AstraZeneca; Barbara Ann Karmanos Cancer Institute; Columbia University; Daiichi Sankyo Company; Memorial Sloan-Kettering Cancer Center; Merck & Co; National Cancer Institute (USA); Plexxikon; The Christie NHS Foundation Trust; University of California at San Francisco
  • Class 2 ring heterocyclic compounds; Antidementias; Antineoplastics; Fluorine compounds; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Macrophage colony stimulating factor receptor antagonists; Proto oncogene protein c-kit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Giant cell tumour of tendon sheath
  • Phase II Acral lentiginous melanoma; Glioblastoma; Malignant melanoma; Prostate cancer
  • Phase I/II Acute myeloid leukaemia; Breast cancer; Gastrointestinal stromal tumours; Leukaemia; Sarcoma; Solid tumours
  • No development reported Colorectal cancer; Pancreatic cancer
  • Discontinued Alzheimer's disease; Hodgkin's disease; Neurological disorders; Rheumatoid arthritis

Most Recent Events

  • 28 Oct 2021 Updated adverse events and pharmacokinetics data from a phase I trial (In volunteers) presented at the annual meeting of American College of Clinical Pharmacology (ACCP-2021)
  • 13 Sep 2021 Pharmacokinetics and adverse events data from a phase I pharmacokinetics trial presented at the annual meeting of the American College of Clinical Pharmacology (ACCP-2021 (3608930)
  • 28 May 2021 Daiichi Sankyo completes a phase I clinical trial in Solid tumours (Second-line therapy or greater, late-stage disease) in Taiwan (PO) (NCT02734433)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top